The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
Open accessAbstract
Abstract Purpose: Indoleamine 2,3-dioxygenase-1 (IDO1) catalyzes the degradation of tryptophan to N-formyl-kynurenine. Overexpressed in many solid malignancies, IDO1 can promote tumor escape from host immunosurveillance. This first-in-human phase I study investigated the maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of epacadostat (INCB024360), a potent and selective inhibitor of IDO1. Experimental Design: Fifty-two patients with advanced solid malignancies were treated with epacadostat [50 mg once daily or 50, 100, 300, 400, 500, 600, or 700 mg twice daily (BID)] in a dose-escalation 3 + 3 design and evaluated in 28-day cycles. Treatment was continued until disease progression or unacceptable toxicity. Results: One dose-limiting toxicity (DLT) occurred at the dose of 300 mg BID (grade 3, radiation pneumonitis); another DLT occurred at 400 mg BID (grade 3, fatigue). The most common adverse events in >20% of patients overall were fatigue, nausea, decreased appetite, vomiting, constipation, abdominal pain, diarrhea, dyspnea, back pain, and cough. Treatment produced significant dose-dependent reductions in plasma kynurenine levels and in the plasma kynurenine/tryptophan ratio at all doses and in all patients. Near maximal changes were observed at doses of ≥100 mg BID with >80% to 90% inhibition of IDO1 achieved throughout the dosing period. Although no objective responses were detected, stable disease lasting ≥16 weeks was observed in 7 of 52 patients. Conclusions: Epacadostat was generally well tolerated, effectively normalized kynurenine levels, and produced maximal inhibition of IDO1 activity at doses of ≥100 mg BID. Studies investigating epacadostat in combination with other immunomodulatory drugs are ongoing. Clin Cancer Res; 23(13); 3269–76. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Regarding dosing of epacadostat, 100 mg was taken forward out of the phase I study despite higher dose levels being tolerable and no maximum tolerated dose being established (59).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Self-citationPrevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I. E., Conway, S. J., Marshall, B., Brown, C. C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,589
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Self-citationAn Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., & Bradfield, C. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903670 · Cited by 1,674
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I. E., Pashine, A., & Mellor, A. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,640
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Frumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U., & Ferrara, G. B. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020121 · Cited by 1,133
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,093
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Beatty, G. L., & Gladney, W. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1860 · Cited by 1,078
Self-citationMuller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
Platten, M., Wick, W., & den Eynde, B. J. V. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0569 · Cited by 725
Holmgaard, R., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 646
Brandacher, G., Perathoner, A., Ladurner, R., Schneeberger, S., Obrist, P., Winkler, C., Werner, E. R., Werner-Felmayer, G., Weiss, H. G., G√∂bel, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1966 · Cited by 614
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Liu, X., Shin, N., Koblish, H. K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M., Thomas, B. A., Rupar, M. J., et al. (2010) · Blood · doi:10.1182/blood-2009-09-246124 · Cited by 559
Self-citationSpranger, S., Koblish, H. K., Horton, B., Scherle, P. A., Newton, R., & Gajewski, T. F. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-3 · Cited by 552
Self-citationIDO Activates Regulatory T Cells and Blocks Their Conversion into Th17-Like T Cells
Baban, B., Chandler, P., Sharma, M. D., Pihkala, J. P. S., Koni, P. A., Munn, D. H., & Mellor, A. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900986 · Cited by 494
Chiesa, M. D., Carlomagno, S., Frumento, G., Balsamo, M., Cantoni, C., Conte, R., Moretta, L., Moretta, A., & Vitale, M. (2006) · Blood · doi:10.1182/blood-2006-03-006700 · Cited by 417
Sharma, M. D., Hou, D., Liu, Y., Koni, P. A., Metz, R. A., Chandler, P., Mellor, A. L., He, Y., & Munn, D. H. (2009) · Blood · doi:10.1182/blood-2008-12-195354 · Cited by 406
Okamoto, A., Nikaido, T., Ochiai, K., Takakura, S., Saito, M., Aoki, Y., Ishii, N., Yanaihara, N., Yamada, K., Takikawa, O., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2671 · Cited by 399
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Godin-Ethier, J., Hanafi, L., Piccirillo, C. A., & Lapointe, R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1331 · Cited by 398
Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
Ino, K., Yoshida, N., Kajiyama, H., Shibata, K., Yamamoto, E., Kidokoro, K., Takahashi, N. K., Terauchi, M., Nawa, A., Nomura, S., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603477 · Cited by 249
Koblish, H. K., Hansbury, M., Bowman, K., Yang, G., Neilan, C. L., Haley, P. J., Burn, T. C., Waeltz, P., Sparks, R. B., Yue, E. W., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0628 · Cited by 243
Self-citationInaba, T., Ino, K., Kajiyama, H., Yamamoto, E., Shibata, K., Nawa, A., Nagasaka, T., Akimoto, H., Takikawa, O., & Kikkawa, F. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.07.015 · Cited by 220
Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase
Ravishankar, B., Liu, H., Shinde, R. S., Chandler, P., Baban, B., Tanaka, M., Munn, D. H., Mellor, A. L., Karlsson, M. C. I., & McGaha, T. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117736109 · Cited by 201
Grohmann, U., Fallarino, F., Bianchi, R., Belladonna, M. L., Vacca, C., Orabona, C., Uyttenhove, C., Fioretti, M. C., & Puccetti, P. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.2.708 · Cited by 175
Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality
Jasperson, L. K., Bucher, C. M., Panoskaltsis‐Mortari, A., Taylor, P. A., Mellor, A. L., Munn, D. H., & Blazar, B. R. (2007) · Blood · doi:10.1182/blood-2007-06-096081 · Cited by 145
Takao, M., Okamoto, A., Nikaido, T., Urashima, M., Takakura, S., Saito, M., Saito, M., Okamoto, S., Takikawa, O., Sasaki, H., et al. (2007) · Oncology Reports · doi:10.3892/or.17.6.1333 · Cited by 97
Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer
Kreamer, K. M. (2014) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2014.5.6.3 · Cited by 61
Gangadhar, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Olszanski, A. J., Luke, J. J., Balmanoukian, A. S., Kaufman, D. R., Zhao, Y., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw379.06 · Cited by 58
Self-citationGibney, G. T., Hamid, O., Lutzky, J., Olszanski, A. J., Gangadhar, T. C., Gajewski, T. F., Chmielowski, B., Hanks, B. A., Boasberg, P. D., Zhao, Y., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)30312-4 · Cited by 34
Self-citation
Research works printed but not linked: 1
- Gangadhar, 2016, Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037, Ann Oncol, 27, vi381, 10.1093/annonc/mdw379.06 · DOI
Cited by
Sorted by citations
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,620
Natural killer cells and other innate lymphoid cells in cancer
Chiossone, L., Dumas, P., Vienne, M., & Vivier, É. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0061-z · Cited by 1,034
Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A., Carlino, M. S., Grob, J.-J., Kim, T. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30274-8 · Cited by 960
Self-citationNext generation of immune checkpoint therapy in cancer: new developments and challenges
Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0582-8 · Cited by 819
Metadata
- Authors
- Beatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Bowman, K. J., Scherle, P. A., Newton, R. C., Schaub, R., Maleski, J., Leopold, L., & Gajewski, T. F.
- Affiliations
- Abramson Cancer Center (US)
- Incyte (United States) (US)
- University of Chicago (US)
- Corresponding author
- Beatty, Gregory L.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2017-07-01
- Volume
- 23
- Issue
- 13
- Pages
- 3269-3276
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC5496788
- OpenAlex
- W2570766240
- Cited by
- 314
- References
- 40
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 42 · 2023: 21 · 2022: 26 · 2021: 36 · 2020: 33 · 2019: 44 · 2018: 53 · 2017: 24
- FWCI
- 18.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Chicago
- Abramson Cancer Center
- National Cancer Institute (K08CA138907)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- epacadostat, IDO1, IDO1 inhibitors, advanced solid tumors, kynurenine, kynurenine/tryptophan ratio, tryptophan degradation, tumor immunosuppression, radiation pneumonitis, dose-limiting toxicity, pharmacokinetics, pharmacodynamics, anticancer activity, maximum tolerated dose
- MeSH terms
- Administration, Oral, Adult, Aged, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasm Staging, Neoplasms, Oximes, Sulfonamides, Indoleamine-Pyrrole 2,3,-Dioxygenase, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
